Editorial comment.
Tan
Winston W
WW
D000726:Androgen Antagonists / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000517:prevention & control*; D004164:Diphosphonates / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D009919:Orchiectomy; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000628:therapy*; D012720:Severity of Illness Index; D000077211:Zoledronic Acid
D000726:Androgen Antagonists; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D007987:Gonadotropin-Releasing Hormone; D000077211:Zoledronic Acid